## Special Issue

# Diabetes Mellitus: Current Research and Future Perspectives

## Message from the Guest Editor

The heterogeneity in age at onset and clinical presentation within the same form of diabetes, differences in the response to treatments in patients with the same phenotype, as well as the variability in the course of the disease require personalized management. The precision medicine approach has been applied to individuals with monogenic diabetes (i.e., MODY, neonatal diabetes) and to type 1 and type 2 diabetes, to select treatments that are most likely to offer benefits and least likely to cause side effects, with improvement of clinical outcomes and economic cost saving. In the last 10 years, genetic, metabolomic, immunologic, and other sophisticated tests have become less expensive and more widespread; therefore, it is expected that precision medicine will become increasingly applied to diabetes care. This Special Issue of the Journal of Personalized *Medicine* aims to highlight the current state of precision medicine applied to diabetes, to show some of the latest findings and future perspectives, and to integrate expertise from basic science, clinical, and populationbased approaches.

### **Guest Editor**

Dr. Roberto Franceschi Pediatric Unit, S. Chiara Hospital, 38122 Trento, Italy

### Deadline for manuscript submissions

closed (20 February 2024)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



### mdpi.com/si/126148

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

### Editor-in-Chief

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

